Article
Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.
Cancer chemotherapy and pharmacology - 1 Jun 2013
Yamamoto Noboru, Nokihara Hiroshi, Yamada Yasuhide, Uenaka Kazunori, Sekiguchi Risa, Makiuchi Takeshi, Slapak Christopher A, Benhadji Karim A, Tamura Tomohide
Abstract excerpt
PURPOSE: LY2334737 is an oral gemcitabine prodrug. This Phase I study assessed the safety and tolerability of LY2334737 in Japanese patients with solid tumors and evaluated pharmacokinetics (PK), pharmacodynamics, and antitumor activity. METHODS: Patients with advanced/metastatic solid tumors received escalating doses of LY2334737 once daily for 14 days, followed by a 7-day drug-free period. Cycles were repeated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.